Tinea pedis
diseaseOn this page
Also known as athlete's footdermatophytosis of footdermatophytosis of pespes dermatophytosis
Summary
Tinea pedis (MONDO:0005984) is a disease with 19 GWAS associations across 8 studies and 56 clinical trials. Top therapeutic interventions include naftifine, terbinafine, and ketoconazole. A subtype of dermatophytosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 19
- Clinical trials: 56
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | tinea pedis |
| Mondo ID | MONDO:0005984 |
| EFO | EFO:0007512 |
| MeSH | D014008 |
| DOID | DOID:12403 |
| ICD-10-CM | B35.3 |
| SNOMED CT | 6020002 |
| UMLS | C0040259 |
| MedGen | 52759 |
| Anatomy (UBERON) | UBERON:0002387 |
| Is cancer (heuristic) | no |
Also known as: athlete’s foot · dermatophytosis of foot · dermatophytosis of pes · pes dermatophytosis
Data availability: 19 GWAS associations (8 studies).
Disease family
This is a subtype of dermatophytosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis › tinea infection › dermatophytosis › tinea pedis
Related subtypes (10): tinea barbae, ectothrix infectious disease, endothrix infectious disease, dermatophytosis of groin and perianal area, tinea corporis, tinea unguium, tinea profunda, tinea manuum, dermatophytosis of scalp or beard, Majocchi granuloma
Genetics & variants
GWAS landscape
19 GWAS associations across 8 studies. Top hits map to 9 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs11642192 | 2e-55 | ZNF668 | C | 0.1 |
| chr16:31060647 | 7e-32 | G | 0.13 | |
| rs55818528 | 1e-31 | LYNX1-SLURP2 - LY6D | G | 0.07 |
| rs2572925 | 8e-25 | LY6D | C | 0.09 |
| rs12122629 | 7e-19 | TCHHL1 - TCHH | C | 0.15 |
| rs1794269 | 2e-15 | HLA-DQB1 - MTCO3P1 | T | 0.05 |
| chr8:143858846 | 4e-14 | G | 0.09 | |
| rs184587444 | 4e-14 | SPRR2B - SPRR2E | T | 0.22 |
| chr1:152448098 | 7e-14 | A | 0.2 | |
| rs12123821 | 7e-13 | CCDST | C | 0.19 |
| rs34434863 | 2e-11 | HLA-DRB1 - HLA-DQA1 | T | 0.07 |
| rs4796793 | 2e-11 | STAT3 - CAVIN1 | C | 0.05 |
| rs111648091 | 4e-11 | STAT3 | T | 0.22 |
| rs640081 | 7e-10 | FAIM2 | A | 0.04 |
| rs12434646 | 2e-09 | AREL1 | T | 0.06 |
| rs648802 | 7e-09 | PERP | C | 0.04 |
| rs533386 | 2e-08 | JAK1 | C | 0.05 |
| rs61999117 | 2e-07 | SNRPN | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90475563 | Verma A | 2024 | 17,658 | 408,239 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477148 | Verma A | 2024 | 10,143 | 101,121 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479766 | Verma A | 2024 | 10,143 | 101,121 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477147 | Verma A | 2024 | 3,487 | 52,105 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651990 | Liu TY | 2025 | 2,157 | 223,436 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90481460 | Verma A | 2024 | 235 | 6,334 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435559 | Zhou W | 2018 | 141 | 406,301 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90809872 | Haapaniemi H | 2026 | 0 | 0 | The genetic basis of dermatophytosis skin infection susceptibility. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 2 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 1 |
| Tier 4: intronic/intergenic | 15 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 14 |
| low_freq (0.01-0.05) | 4 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 7 |
| intergenic_variant | 4 |
| unknown | 3 |
| missense_variant | 2 |
| regulatory_region_variant | 1 |
| non_coding_transcript_exon_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs11642192 | 16 | 31070704 | T>C | 0.413 | intron_variant | ZNF668 | 2e-55 | Tier 4: intronic/intergenic |
| chr16:31060647 | 0.376 | 7e-32 | Tier 4: intronic/intergenic | |||||
| rs55818528 | 8 | 142780034 | T>C,G | 0.379 | intergenic_variant | LYNX1-SLURP2 - LY6D | 1e-31 | Tier 4: intronic/intergenic |
| rs2572925 | 8 | 142786489 | C>G,T | 0.401 | missense_variant | LY6D | 8e-25 | Tier 1: coding |
| rs12122629 | 1 | 152101640 | A>C,T | 0.039 | intergenic_variant | TCHHL1 - TCHH | 7e-19 | Tier 4: intronic/intergenic |
| rs1794269 | 6 | 32706117 | C>G,T | 0.4 | intergenic_variant | HLA-DQB1 - MTCO3P1 | 2e-15 | Tier 4: intronic/intergenic |
| chr8:143858846 | 0.386 | 4e-14 | Tier 4: intronic/intergenic | |||||
| rs184587444 | 1 | 153079185 | C>T | 0.016 | intron_variant | SPRR2B - SPRR2E | 4e-14 | Tier 4: intronic/intergenic |
| chr1:152448098 | 0.063 | 7e-14 | Tier 4: intronic/intergenic | |||||
| rs12123821 | 1 | 152206676 | C>T | 0.037 | intron_variant | CCDST | 7e-13 | Tier 4: intronic/intergenic |
| rs34434863 | 6 | 32591896 | T>A,C,G | 0.256 | intergenic_variant | HLA-DRB1 - HLA-DQA1 | 2e-11 | Tier 4: intronic/intergenic |
| rs4796793 | 17 | 42390192 | G>A,C | 0.275 | regulatory_region_variant | STAT3 - CAVIN1 | 2e-11 | Tier 3: regulatory |
| rs111648091 | 17 | 42378157 | T>C | 0.016 | intron_variant | STAT3 | 4e-11 | Tier 4: intronic/intergenic |
| rs640081 | 12 | 49896771 | G>A,C,T | 0.342 | intron_variant | FAIM2 | 7e-10 | Tier 4: intronic/intergenic |
| rs12434646 | 14 | 74711990 | C>A,T | 0.435 | non_coding_transcript_exon_variant | AREL1 | 2e-09 | Tier 4: intronic/intergenic |
| rs648802 | 6 | 138092196 | G>A,C,T | 0.456 | missense_variant | PERP | 7e-09 | Tier 1: coding |
| rs533386 | 1 | 65019448 | A>C,T | 0.162 | intron_variant | JAK1 | 2e-08 | Tier 4: intronic/intergenic |
| rs61999117 | 15 | 24868138 | C>T | 0.05 | intron_variant | SNRPN | 2e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
7 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Ciclopirox | Approved (phase 4) |
| Clotrimazole | Approved (phase 4) |
| Griseofulvin | Approved (phase 4) |
| Ketoconazole | Approved (phase 4) |
| Luliconazole | Approved (phase 4) |
| Miconazole | Approved (phase 4) |
| Tolnaftate | Approved (phase 4) |
| Dapaconazole | Phase 3 (in late-stage trials) |
| Econazole | Phase 3 (in late-stage trials) |
| Fluconazole | Phase 3 (in late-stage trials) |
| Naftifine | Phase 3 (in late-stage trials) |
| Terbinafine | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Berdazimer Sodium, Bifonazole, Isotretinoin, Itraconazole, Nitric Oxide, Nitrogen, Oteseconazole, Oxygen, Prednicarbate.
Clinical trials & evidence
Clinical trials
Clinical trials: 56.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 19 |
| PHASE2 | 16 |
| PHASE1 | 10 |
| Not specified | 6 |
| PHASE4 | 4 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06869681 | PHASE4 | NOT_YET_RECRUITING | Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis |
| NCT01712360 | PHASE4 | COMPLETED | Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis |
| NCT02394340 | PHASE4 | COMPLETED | Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris |
| NCT02767271 | PHASE4 | COMPLETED | Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris |
| NCT00750139 | PHASE3 | COMPLETED | Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis |
| NCT00802672 | PHASE3 | COMPLETED | Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis |
| NCT00856596 | PHASE3 | UNKNOWN | Once a Day Topical Treatment for Athlete’s Foot Fungus Inbetween the Toes in Males and Females |
| NCT01105013 | PHASE3 | UNKNOWN | Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections |
| NCT01110330 | PHASE3 | TERMINATED | An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete’s Foot |
| NCT01289015 | PHASE3 | COMPLETED | Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis |
| NCT01290341 | PHASE3 | COMPLETED | Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis |
| NCT01349998 | PHASE3 | COMPLETED | Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis |
| NCT01353976 | PHASE3 | COMPLETED | Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis |
| NCT01358240 | PHASE3 | COMPLETED | Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis |
| NCT01396785 | PHASE3 | COMPLETED | Topical Antifungal Treatment for Tinea Pedis |
| NCT01396811 | PHASE3 | COMPLETED | Topical Antifungal Treatment for Tinea Pedis |
| NCT01433107 | PHASE3 | COMPLETED | Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis |
| NCT02606383 | PHASE3 | WITHDRAWN | Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis |
| NCT02633813 | PHASE3 | COMPLETED | BE Study of Naftifine HCL |
| NCT03129321 | PHASE3 | COMPLETED | Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis |
| NCT03320486 | PHASE3 | COMPLETED | Non-inferiority Trial of Dapaconazole Versus Ketoconazole |
| NCT03824912 | PHASE3 | COMPLETED | Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis |
| NCT04203342 | PHASE3 | COMPLETED | A Therapeutic Equivalence Study of Ketoconazole Cream 2% |
| NCT07245667 | PHASE2 | RECRUITING | Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study |
| NCT00768599 | PHASE2 | COMPLETED | A Study of Econazole Foam 1% in Athlete’s Foot |
| NCT00869336 | PHASE2 | COMPLETED | Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete’s Foot) |
| NCT00893880 | PHASE2 | COMPLETED | A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis |
| NCT01013909 | PHASE2 | COMPLETED | Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo |
| NCT01096472 | PHASE2 | COMPLETED | Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis |
| NCT01891305 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis |
| NCT02824926 | PHASE2 | COMPLETED | Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis |
| NCT02842021 | PHASE2 | TERMINATED | Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis |
| NCT02860052 | PHASE2 | COMPLETED | SB208 for the Treatment of Tinea Pedis |
| NCT02871011 | PHASE2 | COMPLETED | Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete’s Foot |
| NCT03135912 | PHASE2 | COMPLETED | Three-Arm Trial of Novel Treatment for Tinea Pedis |
| NCT03897257 | PHASE2 | COMPLETED | A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis |
| NCT03999437 | PHASE2 | UNKNOWN | SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS |
| NCT04152226 | PHASE2 | COMPLETED | A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis |
| NCT05493488 | PHASE2 | UNKNOWN | A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis |
| NCT00509275 | PHASE1 | COMPLETED | A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NAFTIFINE | 4 | 11 |
| TERBINAFINE | 4 | 5 |
| KETOCONAZOLE | 4 | 4 |
| LEVOKETOCONAZOLE | 4 | 4 |
| CLOTRIMAZOLE | 4 | 3 |
| BUTENAFINE | 4 | 2 |
| BERDAZIMER SODIUM | 4 | 1 |
| ESOMEPRAZOLE | 4 | 1 |
| NITRIC OXIDE | 4 | 1 |
| OMEPRAZOLE | 4 | 1 |
| OTESECONAZOLE | 4 | 1 |
| PREDNICARBATE | 4 | 1 |
| SERTACONAZOLE | 4 | 1 |
| DAPACONAZOLE | 3 | 3 |
| SODIUM LAURYL SULFATE | 3 | 1 |
| ALBACONAZOLE | 2 | 1 |
| OCTENIDINE HYDROCHLORIDE | 2 | 1 |
| AN-2718 | 1 | 1 |
| CHEMBL328863 | 0 | 4 |
| CHEMBL75 | 0 | 4 |
| VEHICLE | 0 | 2 |
| CHEMBL1204779 | 0 | 1 |